Literature DB >> 11672920

A combination vaccine confers full protection against co-infections with influenza, herpes simplex and respiratory syncytial viruses.

A M Talaat1, R Lyons, S A Johnston.   

Abstract

Combined/composite vaccines should be useful in reducing the number of vaccinations and provide more flexibility in confronting biological warfare scenarios. We tested the effectiveness of a composite genetic vaccine designed from previously known protective antigens directed against influenza A virus (INF-A), herpes simplex virus type-1 (HSV-1) and respiratory syncytial virus (RSV) in a mouse-based challenge. Immunizing mice with a pool of four plasmids; INF-A haemagglutinin (HA), INF-A nucleoprotein (NP), HSV-1 glycoprotein D (gD) and RSV glycoprotein F, against the three pathogens provided full protection when mice were challenged with each pathogen. Remarkably, mice challenged with all three pathogens at once were also fully protected, even when a bacterial pathogen, Mycoplasma pulmonis, was included in the challenge. If these results are extendable to other combinations of vaccines in other hosts, it would support the development of gene vaccines as multi-component, combination vaccines.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11672920     DOI: 10.1016/s0264-410x(01)00352-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

Review 1.  Expression library immunization: a road map for discovery of vaccines against infectious diseases.

Authors:  Adel M Talaat; Katherine Stemke-Hale
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

2.  Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector.

Authors:  Luis Martinez-Sobrido; Negin Gitiban; Ana Fernandez-Sesma; Jerome Cros; Sara E Mertz; Nancy A Jewell; Sue Hammond; Emilio Flano; Russell K Durbin; Adolfo García-Sastre; Joan E Durbin
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

3.  The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods.

Authors:  Shixia Wang; Chunghua Zhang; Lu Zhang; Jun Li; Zuhu Huang; Shan Lu
Journal:  Vaccine       Date:  2008-03-06       Impact factor: 3.641

4.  Localized and Systemic Immune Responses against SARS-CoV-2 Following Mucosal Immunization.

Authors:  Shaswath S Chandrasekar; Yashdeep Phanse; Rachel E Hildebrand; Mostafa Hanafy; Chia-Wei Wu; Chungyi H Hansen; Jorge E Osorio; M Suresh; Adel M Talaat
Journal:  Vaccines (Basel)       Date:  2021-02-06

5.  Novel immune-modulator identified by a rapid, functional screen of the parapoxvirus ovis (Orf virus) genome.

Authors:  Michael J McGuire; Stephen A Johnston; Kathryn F Sykes
Journal:  Proteome Sci       Date:  2012-01-13       Impact factor: 2.480

Review 6.  Recent advances in diagnosis, prevention, and treatment of human respiratory syncytial virus.

Authors:  Swapnil Subhash Bawage; Pooja Munnilal Tiwari; Shreekumar Pillai; Vida Dennis; Shree Ram Singh
Journal:  Adv Virol       Date:  2013-12-09

7.  Protective efficacy and immunogenicity of a combinatory DNA vaccine against Influenza A Virus and the Respiratory Syncytial Virus.

Authors:  Viktoria Stab; Sandra Nitsche; Thomas Niezold; Michael Storcksdieck Genannt Bonsmann; Andrea Wiechers; Bettina Tippler; Drew Hannaman; Christina Ehrhardt; Klaus Uberla; Thomas Grunwald; Matthias Tenbusch
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.